GTBP — GT Biopharma Share Price
0.000.00%
Last trade - 00:00- $5.91m
- $1.96m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | -453.55% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
GT Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of immuno-oncology therapeutic products based on its proprietary Tri-specific Killer Engager (TriKE) natural killer (NK) cell engager platform. Its TriKE platform is designed to harness and enhance the cancer-killing abilities of a patient’s immune system’s natural killer cells. Its product candidate pipeline includes GTB-3550, GTB-3650, GTB-5550, GTB-7550, GTB-6550, GTB-1050, and other product candidates. GTB-3550 is a TriKE comprised of two single-chain variable fragments (scFv) composed of the variable regions of the heavy and light chains of anti-CD16 and anti-CD33 antibodies and a modified form of IL-15. GTB-3650 is a TriKE which targets CD33 on the surface of myeloid leukemias. The Company also has a worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE technology.
Directors
- Michael Breen CHM (58)
- Gregory Berk CEO (60)
- Bruce Wendel NVC (67)
- Gavin Choy CFO
- Geoffrey Miller CSO
- Rajesh Shrotriya IND (76)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- October 15th, 1973
- Public Since
- October 22nd, 2013
- No. of Shareholders
- 28
- No. of Employees
- 1
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 2,536,397
- Address
- 505 MONTGOMERY STREET, 10TH FLOOR, SAN FRANCISCO, 94111
- Web
- https://www.gtbiopharma.com/
- Phone
- +1 3105514020
- Auditors
- WEINBERG & COMPANY PA
Upcoming Events for GTBP
GT Biopharma Inc Annual Shareholders Meeting
Q2 2025 GT Biopharma Inc Earnings Release
Q2 2025 GT Biopharma Inc Earnings Release
Similar to GTBP
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
FAQ
What is the GT Biopharma share price?
As of Today at 20:59 UTC, shares in GT Biopharma are trading at $2.33. This share price information is delayed by 15 minutes.
How has the GT Biopharma share price performed this year?
Shares in GT Biopharma last closed at $2.33 and the price had moved by -27.07% over the past 365 days. In terms of relative price strength the GT Biopharma share price has underperformed the S&P500 Index by -34.24% over the past year.
What are the analyst and broker recommendations for GT Biopharma?
The overall consensus recommendation for GT Biopharma is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the GT Biopharma dividend yield?
GT Biopharma does not currently pay a dividend.
Does GT Biopharma pay a dividend?
GT Biopharma does not currently pay a dividend.
When does GT Biopharma next pay dividends?
GT Biopharma does not currently pay a dividend.
How do I buy GT Biopharma shares?
To buy shares in GT Biopharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of GT Biopharma?
As of the previous close price of $2.33, shares in GT Biopharma had a market capitalisation of $5.91m.
Where are GT Biopharma shares listed?
Here are the trading details for GT Biopharma:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: GTBP
What kind of share is GT Biopharma?
Based on an overall assessment of its quality, value and momentum GT Biopharma is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a GT Biopharma share price forecast for 2025?
The analyst consensus target price for shares in GT Biopharma is $11.00. That is 372.1% above the last closing price of $2.33.
Analysts covering GT Biopharma currently have a consensus Earnings Per Share (EPS) forecast of -$2.29 for the next financial year.
Find out moreWhat is the trend in the GT Biopharma share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like GT Biopharma. Over the past six months, its share price has underperformed the S&P500 Index by -21.19%.
As of the last closing price of $2.33, shares in GT Biopharma were trading -4.65% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the GT Biopharma PE Ratio?
The GT Biopharma PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $2.33.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of GT Biopharma?
GT Biopharma's management team is headed by:
- Michael Breen - CHM
- Gregory Berk - CEO
- Bruce Wendel - NVC
- Gavin Choy - CFO
- Geoffrey Miller - CSO
- Rajesh Shrotriya - IND